Hypothesis. Hepatocellular carcinoma (HCC) is one of the most malignant human tumors and one of the risk factors is its highly metastatic property. Coptidis Rhizoma aqueous extract (CRAE) is able to suppress the migration and invasion of HCC cells, MHCC97-L, and F-actin reorganization and Rho signaling inhibition is involved. Main methods. CRAE was prepared and analyzed by high-performance liquid chromatography combined with mass spectrometry. The cytotoxicity and antimigration action of CRAE on MHCC97-L cells were evaluated; Immunofluorescence and immunoblotting were used to investigate the proposed mechanism of CRAE action. Key findings. Chemical analysis reveals that the active components in CRAE are berberine and berberine-like alkaloids. CRAE exhibits a significant inhibitory effect on MHCC97-L cell migration as indicated by wound-healing and invasion-chamber assays. No significant alteration of matrix metalloproteinases and urokinase-type plasminogen activator (uPA) expression were observed in MHCC97-L cells exposed to CRAE. Reduction of F-actin polymerization and damage to cytoskeleton network in MHCC97-L cells were observed after CRAE treatment. Furthermore, it was found that CRAE significantly downregulated the Rho/ROCK signaling pathway. Significance. These results indicate that CRAE may act as a Rho/ROCK signaling inhibitor to suppress MHCC97-L cell migration in vitro and suggested that total alkaloids in Coptidis Rhizoma may be a potential agent for suppressing liver cancer invasion.
Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent human malignancies in the world. 1, 2 Each year there are approximately 500 000 new cases of HCC worldwide, 80% of which are in Asia and Africa. 3 HCC represents the second most common cancer in men and the ninth in women in Hong Kong and accounts for approximately 11.8% of the cancer death rate in 2002. 4 One of the obstacles in HCC therapy is the highly metastatic property of liver cancer cells. Extensive studies have tried to elucidate the process and mechanism involved in cancer metastasis during which cancer cells migrate from one site to another. Some molecules and signaling transduction pathways have been identified as critical factors, such as E-cadherin, catenin, matrix metalloproteinases (MMPs), and the actin cytoskeleton, 5 and molecules targeted to these factors for the purpose of cancer therapy have been reported. [6] [7] [8] However, antimetastatic drugs with effective action and clear mechanism are far from development.
Coptidis Rhizoma (CR, huanglian in Chinese) is a traditional Chinese medicinal herb with a long history of utilization in heat clearing and toxic scavenging. Extensive modern research on the pharmacological action of CR revealed its potential as an anti-inflammatory, 9 antiviral, 10 antibacterial, 11 and antioxidative agent. 12 Our screening study demonstrated that CR aqueous extract (CRAE) exhibited the strongest inhibitory activity on the growth of tumor cells among 16 traditional Chinese anticancer medicinal herbs. 13 Moreover, our clinical study on the therapeutic effect of CR in liver diseases and cancer showed that CR may be used for liver cancer therapy. 14 A number of studies have been carried out on cytotoxic, apoptotic effects and mechanisms of CR and berberine in vitro and in vivo, 15 but there have been no reports on the anti-invasive action of CR and its underlying mechanism. Thus, the following questions need to be clarified: Does CR have the anti-invasive effect? Are all signaling pathways of cancer cell migration involved in the anti-invasive effect of CR? Is the Rho/ROCK signaling pathway specific for anti-invasive effect of CR?
In this study, we report a significant inhibitory effect of CRAE on the migration of an HCC cell line with highly metastatic property, MHCC97-L cells. Using high-performance liquid chromatography combined with mass spectrometry (HPLC/MS), 7 components were identified as berberinelike alkaloids in CRAE. Studies on the proposed mechanism of CRAE's inhibition of MHCC97-L migration showed that CRAE acts on actin cytoskeleton reorganization as a Rho/ROCK inhibitor. These results shed light on CRAE's potential for liver cancer therapy. At the same time, the results also implied that berberine is a main active compound and other berberine-like alkaloids have synergistic antimigration effects in CRAE.
Materials and Methods

Sample Preparation and Phytochemical Analysis
CR was collected from Sichuan province of China and authenticated as the dried roots of Coptis chinensis Franch (Ranunculaceae) by Dr Feng Yibin under the guidance of the Pharmacopeia of China (2005). Authentication was described as previously reported and toxic elements were tested. 16 To prepare the CRAE, raw material was cut into small pieces, and 500 g of crude huanglian was boiled in 10 times (w/v) of distilled water at 100°C 1 hour (3 times) and then filtered. The filtrate was then evaporated to dryness, and the dry extract powder was collected and stored at -20°C until used. Immediately before use, the extract powder was dissolved in dimethyl sulfoxide (DMSO) and diluted to proper concentration in phosphate-buffered saline and then sterilized by filtration through a 0.2 mm pore filter (Minisart-plus, Sartorius, Goettingen, Germany).
HPLC/MS was introduced to identify the chemical profile of CRAE. Analysis was performed using a reverse-phase C 18 column (Alltech Alltima HP C18, 250 mm × 4.6 mm, 5 mm) as solid phase and methanol-Mill-Q water including 15 mM ammonium acetate (25-75) as mobile phase. The flow rate was 1.0 mL/min. Total ion chromatogram of CRAE was obtained by LCQ Deca XP system (Thermo Finnigan, USA) using conditions as follows: sheath gas flow rate (abr): 40; auxiliary gas flow rate (abr): 40; spray voltage (kV): 4.5; capillary temperature (°C): 300; capillary voltage (V): 20; and tube lens offset voltage (V): 24. Immediately before analysis, berberine (Sigma, USA) and CRAE powder were dissolved in methanol and diluted to the proper concentration. Then, 1 mL of standard or sample solution was injected into the HPLC/MS system, and the content of berberine in CRAE was quantified.
Cell Line and Cell Culture
A human liver cancer cell line with metastatic property, MHCC97-L, was used in our previous study. 17 In this study, MHCC97-L cells were maintained in Dulbecco's modified Eagle's medium with high glucose and incubated in a humidified atmosphere containing 5% CO 2 at 37°C.
Cell Viability Assay
Viable cell number after CRAE treatment was obtained by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, cells were seeded in a 96-well plate with supplemental medium and treated with series concentration of CRAE (2, 4, 8, 16, 32, 64, 128, 256 , and 512 mM) and incubated for 24 to 72 hours. All experiments were conducted parallel with controls (0.1% DMSO). Then, cells were incubated with 15 mL of MTT (5 mg/mL, Sigma, USA) at 37°C for 4 hours. Then, the medium was removed, and 200 mL of DMSO was added to each well. The absorbance of formazan formed was measured at 595 nm by Multiskan MS microplate reader (Labsystems, Finland).
Wound Healing Assay
Cells were seeded in a 6-well plate with 100% confluences. A gap was scraped using a micropipette tip on the cell monolayer. The medium was refreshed, and cells were exposed to 100 or 200 mM CRAE or berberine for 0, 24, or 48 hours. The migration of MHCC97-L cells was observed under a fluorescent microscope with 40× magnification (Carl Ziess, USA).
Invasion-Chamber Assay
An experiment was conducted under the manufacturer's instructions (QCM T 96-well cell invasion assay kit, Millipore, USA). Briefly, the invasion chamber was preactivated by 100 mL of serum-free medium for 1 hour. After rehydration of the chamber, 150 mL of growth medium was added to the feeder tray. Then, 100 mL serum-free media with 1 × 10 4 MHCC97-L cells were placed in the invasion chamber. The cells were exposed to CRAE or berberine with a series of concentrations-12.5, 25, 50, 100, 200, and 400 mMand incubated for 24 hours at 37°C, 5% CO 2 . The amount of cells that invaded from the upper chamber to the feeder tray was measured using 480/520 nm filters set using an LS55 fluorescence/luminescence spectrometer (PerkinElmer, USA).
Matrix Metalloproteinases Assay
The expression of MMPs in MHCC97-L cells with or without CRAE and berberine treatment was evaluated using RayBio Human Matrix Metalloproteinase Antibody Array (RayBiotech, USA) following the manufacturer's instructions. Briefly, cells were maintained in a 75-cm 2 flask in serum-free medium with 80% confluence and treated with 100 mM CRAE or berberine for 48 hours. Medium and cell supernatants were collected as sample solutions for subsequent experiments. To conduct the experiment, membranes were first incubated in 2 mL blocking buffer for 30 minutes. Then, membranes were incubated with sample solution overnight and rinsed with washing buffer. Membranes were then subsequently incubated with biotin-conjugated anti-MMPs and horse radish peroxidase-conjugated streptavidin overnight. The expression of MMPs was detected using a detection buffer and visualized under a chemiluminescence imaging system (BioRad, USA).
Visualization of F-Actin Reorganization by Fluorescent Microscopy
Cells were seeded in 35-mm glass-bottom microwell dishes (MatTek, USA) and then exposed to CRAE or berberine (100, 200 mM) for 24 hours. They were then fixed with 4% paraformaldehyde for 30 minutes and penetrated with 1% Triton X-100 in phosphate-buffered saline for 5 minutes, followed by 30 minutes incubation of 5% bovine serum album (BSA) to block the unspecific binding. Then, 50 mg/mL fluorescein isothiocyanate (FITC) conjugated phalloidin (Sigma, USA) was added to the chambers, and cells were incubated in the dark for 30 minutes. Nuclei were then stained with 1 mg/mL 4',6-diamidino-2-phenylindole (DAPI) for 10 minutes, and cells were visualized under a fluorescent microscope with 400× magnification (Carl Ziess, USA).
RhoA-GTPase Activity
Cells were seeded in a 25-cm 2 flask with 80% confluence and then starved overnight in serum-free medium (Invitrogen, USA). After starvation, cells were treated with full growth medium with or without CRAE or berberine (100 and 200 mM) for 30 minutes. Cell lysate was collected and the RhoA-GTPase activity assay was conducted using a Rho Activation Kit (Thermo-Pierce, USA) according to the manufacturer's instructions. The RhoA-GTPase and total RhoA were detected by immunoblotting.
Immunoblotting
Cells were harvested using a microscraper (Corning, USA) and then lysed with RIPA buffer supplemented with protease inhibitor (1% PMSF, 0.5% apotinin, and 0.5% leupeptin) and phosphatase inhibitor (1 mM Na 3 VO 4 and 1 mM NaF) on ice for 30 minutes and then centrifuged at 14 000 rpm at 4°C for 25 minutes. Equal amounts of protein were resolved by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred onto a polyvinylidene fluoride membrane (BioRad, USA). Then, the membrane was blocked with 5% BSA overnight at 4°C. The membrane was then incubated with primary antibody uPA, ROCK1, and b-actin (Abcam, UK) at 4°C overnight followed by incubation with appropriate secondary antibody (Abcam, UK) at room temperature for 2 hours. The immunoreactivities were detected using the ECL plus kit (GE Healthcare, UK) and visualized using a chemiluminescence imaging system (BioRad, USA).
Statistical Analysis
All data were analyzed by Student's t tests for significant interrelation between treatment and control groups. All data were presented in terms of mean ± standard deviation of the mean. Differences between group means were considered to be statistically significant for P < .05.
Results
Phytochemical Analysis on CRAE
CR contains different berberine-like alkaloids, including berberine, palmatine, jatrorrhizine, columbamine, epiberberine, and coptisine. In this study, a rapid and efficient method was established to identify the chemical composition of the CRAE using high performance liquid chromatography-electro spray ionization-mass spectrometry (HPLC-ESI-MS ) high performance liquid chromatography-electro spray ionization-mass spectrometry (HPLC-ESI-MS). The total ion chromatogram profile ( Figure 1A ) of the extract shows that the CRAE mainly comprised 7 berberine-type compounds. Comparing the mass spectra ( Figure 1B ) with literature reports, 18 peaks 1 to 7 are identified as magnoflorine, columbamine, jatrorrhizine, epiberberine, coptisine, palmatine and berberine, respectively (Table 1) . To facilitate the comparison of bioactivity between berberine and equal content of berberine in CRAE, we determined the total alkaloids in CRAE at 348 nm by a UV spectrometric approach, using berberine as a standard. Total alkaloid content of CRAE was expressed as an equal amount of berberine in the later studies. 
Effect of CRAE on the Invasion and Migration of MHCC97-L Cells in Vitro
To study the antimetastatic effect of CRAE on HCC cells MHCC97-L, the wound-healing assay and invasion-chamber assay were introduced to qualitatively and quantitatively determine the migration of MHCC97-L cells with or without exposure to CRAE and its major component berberine. It was observed that MHCC97-L cells at the opposite edges of the wounds rapidly migrated toward each other after 48 hours of incubation ( Figure 3A) . With increasing doses, the speed of wound healing slowed down, the gap remained open, and only minimum cell proliferation on the 2 edges of the wound was observed when cells were incubated with 200 mM of CRAE or berberine. Cell motility was significantly inhibited in the presence of CRAE or its major component berberine. A similar result could be observed in the invasion-chamber assay, where both berberine and CRAE revealed inhibitory effects on the invasion of MHCC97-L through the extracellular matrix ( Figure 3B ). To further our knowledge on CRAE's action on MHCC97-L Figure 3C show that a combination of a low dose of berberine or CRAE and Y-27632 increased their inhibitory effects at low doses compared with Figure 3A , showing that the action of berberine and CRAE on liver-cancer-cell migration is similar to that of a Rho/ROCK inhibitor cells migration, cells were exposed to Y-27632, a Rho/ ROCK signaling inhibitor in the presence or absence of 100 mM CRAE or berberine. The result showed that inhibition of Rho/ROCK signaling can significantly suppress the migration of liver cancer cells MHCC97-L in a dosedependent manner, indicating that Rho/ROCK signaling activation may play an important role in MHCC97-L migration. The combination of Y-27632 with CRAE increased its inhibitory effect at its low dose, revealing that CRAE's action is similar to that of Rho/ROCK inhibitor in liver cancer cell migration ( Figure 3C ).
Effect of CRAE on MMPs and uPA Expression
It was observed that expression of MMP-2 and MMP-9 in MHCC97-L cells remained low, indicating a loose connection between MMP expression and MHCC97-L cell migration ability. Furthermore, both CRAE and berberine did not reduce the expression of MMP-2 and MMP-9 in MHCC97-L cells, but it is interesting to observe that the tissue inhibitor of MMP-4 (TIMP-4), which was reported as an indicator in breast cancer, prostate cancer, and colon cancer, 19 was potently inhibited by CRAE and berberine treatment (Figure 4 ). No significant change in the expression of urokinase-type plasminogen activator (uPA) in MHCC97-L cells with or without exposure of CRAE and berberine was observed in our study ( Figure 5 ), indicating that uPA may not be involved in CRAE's inhibitory effect on HCC cell migration.
Effect of CRAE F-Actin Reorganization in MHCC97-L Cells
The F-actin cytoskeleton in MHCC97-L was potently damaged by CRAE at doses far lower than its IC 50 , indicating that a low dose of CRAE may prominently inhibit the F-actin polymerization and induce damage of the cytoskeleton network of MHCC97-L cells ( Figure 6 ).
Effect of CRAE on Rho/ROCK Signaling Pathway
The GTPase form of RhoA was potently suppressed in MHCC97-L with CRAE and berberine treatment while total RhoA expression remained constant ( Figure 5 ), indicating that CRAE may suppress the activation of RhoA signaling by impeding the cycle between Rho-GDPase and Rho-GTPase. Moreover, CRAE exhibited prominent inhibition of the expression of ROCK-1 ( Figure 5 ). This further proves CRAE acts as an inhibitor of Rho/ROCK signaling to suppress MHCC97-L cell migration. To confirm the role of the Rho/ROCK signaling pathway on effects of CRAE in MHCC97-L cell migration, Y-27632, a Rho/ROCK signaling inhibitor alone or in combination with 100 mM CRAE was used in this study, and the results showed that inhibition of Rho/ROCK signaling could significantly suppress the migration of MHCC97-L cells in a dose-dependent manner, indicating that Rho/ROCK signaling activation may play an important role in MHCC97-L cell migration ( Figure 3C ).
Discussion
HCC is one of the most malignant human cancers in the world. 20, 21 Recurrence after surgical removal and metastasis are common in HCC and are associated with poor prognosis. Effective treatment is in urgent need for improvement of patients' survival. Traditional Chinese medicine as a complementary and alternative treatment for cancer therapy has been widely used in daily clinical treatment. 22 As a commonly used medicinal herb, CR has been extensively investigated for its potent antitumor action. It was reported that CR extract can inhibit cell proliferation by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. 23 CR extract can induce apoptosis by upregulating interferon-b and TNF-a in human breast cancer cells. 24 Recently, we reported that the anti-invasion property of berberine, a pure compound isolated from CR, may inhibit the RhoA signaling pathway at a low dose, whereas apoptosis is induced by berberine via G2 arrest at a high dose in NPC cell lines because of berberine distribution in cell nuclei and cytoplasm in a dose-dependent manner. 25 In this study, we reported the anti-invasive action of CRAE and its major component berberine on HCC cells. Potent action on the F-actin reorganization and RhoA activity inhibition could be observed in cells after CRAE and berberine treatment. With screening on the major signal pathways that may be involved in cancer cell migration and invasion, we found that the inhibitory effect of CRAE and berberine on HCC cell migration is specific. Moreover, we found that CRAE, which is composed of 7 berberine-like alkaloids, showed superior anti-invasive effect to the pure compound berberine. Considering that herbal extracts rather than the pure compound are more commonly used in Chinese Medicine practice, 14 our findings suggest a potential complementary medication for HCC invasion and metastasis. F-actin is one type of stress fiber that regulates cell motility and polarization. With its constant state of flux with new monomers being added at the barbed or plus end and depolymerization at the pointed or minus end, F-actin allows eukaryotic cells to migrate directionally. 26 In cancer cells with a highly metastatic property, active polymerization of F-actin is often reported, and the reduction of the F-actin cytoskeleton could inhibit the migration of cancer cells. [27] [28] [29] In this study, we showed for the first time that CRAE could effectively suppress HCC tumor migration and invasion in vitro, and as its mechanism, we observed that CRAE acts on F-actin, inducing filament reorganization. It also inhibits the Rho/ROCK signaling pathway. In Rho/ROCK signaling-induced cancer cell migration, the cell goes through an amoeboid mode of migration. In this mode, cell migration is independent of integrin function and cell-substrate adhesion, which have pivotal impacts in collective and mesenchymal modes of cell migration. Cells that go through amoeboid migration move within the extracellular matrix by squeezing the cell body, and a rounded morphology can be easily observed. Inhibition of Rho/ROCK signaling was reported to induce elongated morphology. 4 Activation of the Rho small GTPase family, especially RhoA-GTPase, is frequently found in the metastasis of different types of human cancers, [30] [31] [32] and inhibition of Rho-GTPase and ROCK suppresses tumor invasion in vitro and in vivo. [33] [34] [35] [36] These studies indicate that the Rho/ ROCK signaling pathway plays a pivotal role in cancer metastasis. Our result indicates that CRAE has the potential to suppress liver cancer metastasis by inhibiting Rho/ ROCK signaling.
Standard CRAE was used in this study because the clinically used form of CR is its water extract, and it is also a basic unit in making composite formulae. 16, 37 To standardize the quality of CRAE, HPLC/MS/MS was introduced in this study, and we have identified 7 berberine-type alkaloids in CRAE, in which berberine amounts to approximately 23% of the total extract (data not shown). These results suggest that the berberine and berberine-type alkaloids may be the active components in CRAE for the anti-invasive effect on MHCC97-L cells. Some studies have revealed that CR and berberine exhibit positive correlations in their anticancer action in vitro and in vivo. 38, 39 A report demonstrated that CRAE inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells and has better inhibitory effect than berberine. 40 Moreover, recent studies reported that berberine suppresses the metastasis and invasion of Lewis lung carcinoma and human lung cancer cells through the repression of expression of uPA or decreased production of uPA and MMP-2. 41 Our result indicates that the anti-invasive effect of CRAE on the MHCC97-L cell line only acts on F-actin via the Rho/ROCK signaling pathway and not on other metastasis-related molecules such as integrin b4, E-cadherin (data not shown), uPA, and MMPs, indicating that the Rho/ROCK inhibition may be a new mechanism involved in its action against cancer invasion. An inhibitory effect of CRAE on MHCC97-L cell migration was observed, which is consistent with berberine, but the inhibitory effect of CRAE is more potent than that of berberine, indicating that berberine acts as the main active compound in CRAE, whereas other berberine-like alkaloids have a synergistic effect to berberine. The precise role of CRAE and berberine on antimetastasis in animal models needs further investigation.
It should be noted that berberine and CRAE used in this study were at relatively high doses. In some cases, the IC 50 of berberine or CRAE was lower than 4 mg/mL, which is below the safety limit established by the National Cancer Institute. 40, 42 The IC 50 of berberine and CRAE in this study seem rather high, and the reason needs to be further explored in future. However, berberine and CRAE are natural products that have been used widely for many years. As an antimicrobial agent, berberine has been used to cure microbial-related gastric diseases. The dose can be very high, even up to 1 g/d (China Pharmacopeia, 2005 edition). Our other studies also showed that berberine exhibited very low cytotoxicity on rat hepatocytes (data not shown), and CRAE has liver protective effects in the liver damage animal model. 16 These suggest low toxicity of berberine and CRAE and indicate that both can be used at high doses. Because of the potential anticancer effects of berberine and huanglian, demonstrated by in vitro results and Chinese Medicine practice, berberine and CRAE could be promising agents for clinical trials. 15 New molecular targets and dosages of berberine and CRAE used in this study will provide useful information for further studies.
Conclusion
In conclusion, this is the first study to show that CRAE is a potent antimetastatic agent to inhibit MHCC97-L cells, which is a highly invasive cell model for liver cancer. CRAE has a better anti-invasive effect than its main active compound, berberine, suggesting that other berberine-like alkaloids have synergistic effects to berberine. CRAE acts on F-actin, inducing filament reorganization and therefore inhibits MHCC97-L cell motility. The inactivation of the Rho/ROCK signaling pathway involved in CRAE's inhibitory action on MHCC97-L migration indicated CRAE's role as a Rhosmall GTPase inhibitor. This study sheds light on CRAE as an alternative therapy for the treatment of metastatic hepatic carcinoma.
